

**PATENT****IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

PRE APPLICATION OF:

Yasufumi Kaneda

APPLICATION No.: 10/824,757

FILING DATE: 04/14/2004

FOR: VIRUS ENVELOPE VECTOR FOR GENE
TRANSFER

EXAMINER: Whiteman, B.

ART UNIT: 1635

CONF. No.: 7091

**Supplemental Information Disclosure Statement After First Office Action but
Before Final Action or Notice of Allowance – 37 C.F.R. § 1.97(c)**Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

1. Timing of Submission

The information transmitted herewith is being filed *after* three months of the filing date of this application or after the mailing date of the first Office action on the merits, whichever occurred last, but *before* the mailing date of either a final action under 37 C.F.R. § 1.113 or a Notice of Allowance under 37 C.F.R. § 1.311, whichever occurs first. The references listed on the enclosed Form PTO-1449 (modified) may be material to the examination of this application; the Examiner is requested to make them of record in the application.

2. Cited Information

- ☒ Copies of the following references are enclosed:
- ☒ All references except copies of issued patent(s) and published application(s) (see C.F.R. §1.98(a)(2)(i))

3. Effect of Information Disclosure Statement (37 CFR 1.97(h))

This Information Disclosure Statement is not to be construed as a representation that: (i) a search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols,

results and the like reported by third parties are accurate or enabling; or (iv) the cited information is, or is considered to be, material to patentability. In addition, applicant does not admit that any enclosed item of information constitutes prior art to the subject invention and specifically reserves the right to demonstrate that any such reference is not prior art.

4. Fee Payment


- ☒ Applicant elects to pay the fee under 37 CFR 1.17(p) in the amount of \$180.00. A check is enclosed to cover the fee due.
- ☒ The Commissioner is hereby authorized to charge any deficiency in fees to assure timely submission of these papers to Deposit Account No. 50-2207.

5. Patent Term Adjustment (37 CFR 1.704(d))

- ☐ The undersigned states that each item of information submitted herewith was cited in a communication from a foreign patent office in a counterpart application and that this communication was not received by any individual designated in 37 C.F.R. § 1.56(c) more than thirty days prior to the filing of this statement. 37 C.F.R. § 1.704(d).

Respectfully submitted,


Date: May 1, 2006



Jacqueline F. Mahoney
Registration No. 48,390

Correspondence Address:

Customer No. 22918
(650) 838-4300



**Supplemental INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

Form PTO-1449 (Modified)
(Use several sheets if necessary)

COMPLETE IF KNOWN

Application Number	10/824,757
Filed	04/14/2004
First Named Inventor	Yasufumi Kaneda
Group Art Unit	1635
Examiner Name	Whiteman, B.
Atty Dkt No.	59150-8010.US00
Confirmation No.	7091

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	U.S. Patent or Application		Name of Patentee or Inventor of Cited Document	Date of Publication or Filing Date of Cited Document	Pages, Columns, Lines, Where Relevant Figures Appear
		NUMBER	Kind Code (if known)			

FOREIGN PATENT DOCUMENTS

Examiner Initial	Cite No.	Foreign Patent or Application			Name of Patentee or Applicant of Cited Document	Date of Publication or Filing Date of Cited Document	Pages, Columns, Lines, Where Relevant Figures Appear	T
		Office	NUMBER	Kind Code (if known)				

OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published.	T
		Mulligan, <i>Science</i> 260 :926-932, 1993.	
		Ledley, <i>Human Gene Therapy</i> , 6 :1129-1144, 1995.	
		Cole, <i>et al.</i> , <i>J Immunology</i> 158 :4301-4309, 1997.	
		Uchida, <i>et al.</i> , <i>J. Cell Biol.</i> 80 :10-20, 1979.	
		Dzau, <i>et al.</i> , <i>Proc. Natl. Acad. Sci. USA</i> 93 :11421-11425, 1996.	
		Kaneda, <i>et al.</i> , <i>Molecular Medicine Today</i> 5 :298-303, 1999.	
		Okada, <i>et al.</i> , <i>Biken's Journal</i> 4 :209-213, 1961.	
		Bagai, <i>et al.</i> , <i>Journal of Virology</i> 67 (6):3312-3318, 1993.	

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application(s).	